Literature DB >> 10206503

Tuberculin test variability: using the Norwegian Adrenaline-Pirquet method.

H F Jentoft1, E Omenaas, G E Eide, A Gulsvik.   

Abstract

SETTING: Chest Unit, Bergen, Norway.
OBJECTIVES: To study the agreement between two Adrenaline-Pirquet tuberculin tests and compare reactivity in groups read after 2, 3 and 4 days.
DESIGN: Responders from a random sample of 1200 men and women 20-44 years of age in 1991 were tested with dual Adrenaline-Pirquet skin scratch tests with Norwegian-produced synthetic medium tuberculin and read after 2-7 days.
RESULTS: Of 588 subjects dually tuberculin tested, complete agreement existed in 220 (37.4%). A difference of 1 mm one way or the other was observed in 239 (40.6%), whereas a difference of less than 3 mm was found in 567 (96.5%). Using the larger of the two reactions increased the rate of tuberculin positivity (> or =4 mm) by up to 8.4% compared with reading only one of the tests. No statistically significant differences were observed between subjects whose reactions were read after 2, 3 and 4 days.
CONCLUSION: Under the non-blinded conditions of this study the dual Adrenaline-Pirquet tuberculin tests demonstrated reproducibility equivalent to the internationally recommended Mantoux test, and appeared to be independent of time of reading within four days.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10206503

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  2 in total

1.  Absence of relationship between tuberculin reactivity and atopy in BCG vaccinated young adults.

Authors:  E Omenaas; H F Jentoft; W M Vollmer; A S Buist; A Gulsvik
Journal:  Thorax       Date:  2000-06       Impact factor: 9.139

2.  Strong tuberculin response after BCG vaccination is associated with low multiple sclerosis risk: a population-based cohort study.

Authors:  Ola Nakken; Trygve Holmøy; Hein Stigum; Kjell-Morten Myhr; Jesper Dahl; Einar Heldal; Haakon E Meyer
Journal:  Int J Epidemiol       Date:  2022-10-13       Impact factor: 9.685

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.